Bisphosphonate use and atypical femoral fractures: Getting down to brass tacks

Journal of Clinical Endocrinology and Metabolism

Volumn 95, Issue 12, 2010, Pages 5207-5209

  Bauer, Douglas C ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; CORTICOSTEROID; PLACEBO; PROTON PUMP INHIBITOR;

BONE DENSITY; BONE REMODELING; BONE TURNOVER; CLINICAL TRIAL; DRUG EFFICACY; DRUG SAFETY; EDITORIAL; ESOPHAGUS CANCER; FEMUR FRACTURE; HEART ATRIUM FIBRILLATION; HUMAN; JAW OSTEONECROSIS; OSTEOPOROSIS; PRIORITY JOURNAL;

EID: 78650123939     PISSN: 0021972X     EISSN: 0021972X     Source Type: Journal    
DOI: 10.1210/jc.2010-2482     Document Type: Editorial

References (16)

1. Black DM, Schwartz AV, Ensrud KE, Cauley JA, Levis S, Quandt SA, Satterfield S, Wallace RB, Bauer DC, Palermo L, Wehren LE, Lombardi A, Santora AC, Cummings SR 2006 Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial. JAMA 296:2927-2938
2. Black DM, Delmas PD, Eastell R, Reid IR, Boonen S, Cauley JA, Cosman F, Lakatos P, Leung PC, Man Z, Mautalen C, Mesenbrink P, Hu H, Caminis J, Tong K, Rosario-Jansen T, Krasnow J, Hue TF, Sellmeyer D, Eriksen EF, Cummings SR 2007 Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 356:1809-1822 (Pubitemid 46698462)
3. McClung MR, Geusens P, Miller PD, Zippel H, Bensen WG, Roux C, Adami S, Fogelman I, Diamond T, Eastell R, Meunier PJ, Reginster JY 2001 Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group. N Engl J Med 344:333-340
4. Food & Drug Administration 2010 FDA Drug Safety Communication: Safety update for osteoporosis drugs, bisphosphonates, and atypical fractures. www.fda.gov/Drugs/Safety/ucm229009.htm#safety
5. Burr DB 2002 Targeted and nontargeted remodeling. Bone 30:2-4
6. Mashiba T, Hirano T, Turner CH, Forwood MR, Johnston CC, Burr DB 2000 Suppressed bone turnover by bisphosphonates increases microdamage accumulation and reduces some biomechanical properties in dog rib. J Bone Miner Res 15:613-620 (Pubitemid 30174014)
7. Odvina CV, Zerwekh JE, Rao DS, Maalouf N, Gottschalk FA, Pak CY 2005 Severely suppressed bone turnover: a potential complication of alendronate therapy. J Clin Endocrinol Metab 90:1294-1301 (Pubitemid 40463979)
8. Goh SK, Yang KY, Koh JS, Wong MK, Chua SY, Chua DT, Howe TS 2007 Subtrochanteric insufficiency fractures in patients on alendronate therapy: a caution. J Bone Joint Surg Br 89:349-353 (Pubitemid 46563912)
9. Kwek EB, Goh SK, Koh JS, Png MA, Howe TS 2008 An emerging pattern of subtrochanteric stress fractures: a long-term complication of alendronate therapy? Injury 39:224-231
10. Black DM, Kelly MP, Genant HK, Palermo L, Eastell R, Bucci- Rechtweg C, Cauley J, Leung PC, Boonen S, Santora A, de Papp A, Bauer DC; Fracture Intervention Trial Steering Committee; HORIZON Pivotal Fracture Trial Steering Committee 2010 Bisphosphonates and fractures of the subtrochanteric or diaphyseal femur. N Engl J Med 362:1761-1771
11. Abrahamsen B, Eiken P, Eastell R 2009 Subtrochanteric and diaphyseal femur fractures in patients treated with alendronate: a register-based national cohort study. J Bone Miner Res 24:1095-1102
12. Abrahamsen B, Eiken P, Eastell R 2010 Cumulative alendronate dose and the long-term absolute risk of subtrochanteric and diaphyseal femur fractures: a register-based national cohort analysis. J Clin Endocrinol Metab 95:5258-5265
13. Dell R, Greene D, Ott S, Silverman S, Eisemon E, Funahashi T, Adams A, A retrospective analysis of all atypical femur fractures seen in a large California HMO from the years 2007 to 2009. ASBMR 2010 Annual Meeting, Toronto, Canada, 2010
14. Shane E, Burr D, Ebeling PR, Abrahamsen B, Adler RA, Brown TD, Cheung AM, Cosman F, Curtis JR, Dell R, Dempster D, Einhorn TA, Genant HK, Geusens P, Klaushofer K, Koval K, Lane JM, McKiernan F, McKinney R, Ng A, Nieves J, O'Keefe R, Papapoulos S, Sen HT, van der Meulen MC, Weinstein RS, Whyte M 2010 Atypical subtrochanteric and diaphyseal femoral fractures: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 25:2267-2294
15. National Osteoporosis Foundation 2010 Clinician's guide to prevention and treatment of osteoporosis. Washington, DC: National Osteoporosis Foundation
16. Qaseem A, Snow V, Shekelle P, Hopkins Jr R, Forciea MA, Owens DK 2008 Pharmacologic treatment of low bone density or osteoporosis to prevent fractures: a clinical practice guideline from the American College of Physicians. Ann Intern Med 149:404-415 (Pubitemid 351665468)